iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRadimed excels in Q4 2022, anticipates strong growth in 2023

IRadimed's Q4 2022 showcased exceptional performance with record revenues and strong earnings, setting the stage for continued growth.
While facing challenges such as margin pressures and tax expenses, the company's optimistic outlook for 2023 presents growth opportunities.
Strategic focus on revenue expansion, margin improvement, and cost management will be key to sustaining profitability and maximizing shareholder value.
Investors can look forward to potential earnings growth and market positioning strength in the upcoming year.

IRadimed reports record revenue and earnings growth, anticipates FDA clearance

IRadimed's Q1 2023 performance was strong, with record revenue and earnings growth. Despite supply chain challenges, the company is optimistic about FDA clearance for a new product and expects pricing trends to remain favorable.

iRadimed posts record revenue and earnings, raises guidance optimistically

iRadimed delivered exceptional financial performance in Q2 2023, achieving record revenue and substantial earnings growth, driven by strong sales across all product categories.
The company's operational efficiency, margin expansion, and strategic initiatives position it well for sustained growth and profitability in the future.
With raised guidance, innovative product developments, and expanding market presence, iRadimed is poised for continued success and value creation for shareholders.
Investors can be optimistic about iRadimed's performance, as the company demonstrates resilience, growth potential, and a solid foundation for future expansion.

iRadimed reports record Q3 earnings, raises 2023 guidance optimistically

iRadimed (IRMD) delivered exceptional Q3 '23 results, with record revenue, earnings growth, and strong product sales, positioning the company for continued success.
While facing challenges in meeting Q4 '23 targets and securing regulatory approvals, iRadimed's proactive strategies and market opportunities offer avenues for sustained growth.
With raised guidance for 2023 and promising product developments, iRadimed has the potential to capitalize on its strengths and navigate industry challenges effectively.
Investors and stakeholders can look to iRadimed's performance, product innovation, and regulatory progress as indicators of the company's resilience and growth prospects.

iRadimed (IRMD) reports record Q4 revenue, eyes international expansion

iRadimed's Q4 2023 performance marked by record revenue, strong device sales, and margin challenges. The company's focus on product growth and international expansion presents opportunities for future revenue and earnings growth.

iRadimed (IRMD) posts record revenue and earnings growth in Q1 2024

iRadimed (IRMD) delivered strong financial performance in Q1 2024, driven by record revenue, earnings growth, and robust demand for MR patient monitor products.
Despite challenges such as submission delays and significant investment in a new facility, the company remains focused on innovation and shareholder value.
With opportunities for market expansion, product clearance, and operational enhancements, iRadimed is poised for continued growth and competitive strength in the medical device industry.

iRadimed (IRMD) achieves record Q2 earnings, eyes FDA clearance

iRadimed's Q2 2024 performance reflects robust revenue growth, improved margins, and enhanced operational efficiency, positioning the company for continued success.
While facing challenges in international sales and operational delays, iRadimed's focus on cost management and product development presents opportunities for future growth.
Overall, iRadimed's financial outlook remains positive, with strong cash flow, new product developments, and strategic initiatives driving long-term value for investors.

iRadimed posts record Q3 earnings, eyes new product launches

iRadimed's Q3 2024 performance reflects strong revenue growth, operational efficiency, and effective cost management.
While facing challenges in product clearance and sales transition, the company is well-positioned to capitalize on growth opportunities.
Strategic focus on new product launches and international market expansion could drive future revenue and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter Set

IRADIMED CORPORATION Issues Urgent Medical Device Correction

IRadimed came in with a strong set of Q4 and full-year numbers. We noted tremendous momentum on IRMD's profitability front, with strong incremental ROIC on small reinvestment for growth.

IRadimed: Revise To Buy With Exceptional Incremental ROIC In Q4

Revenues rose 25.2% YOY to $14.9 million, due to a rapid acceleration of Patient Monitors and Disposables sales, and a significant contribution from a new product launch. IRMD announced a special cash dividend of $1.05 per share, which is payable to shareholders of record at the close of business on February 13th, 2023.

IRadimed Q4: A Bottom-Line Beat, A Special Cash Dividend, Maintain Buy

IRadimed Corporation (NASDAQ:IRMD ) Q4 2022 Earnings Conference Call February 2, 2023 11:00 AM ET Company Participants Roger Susi - President & CEO Jack Glenn – CFO Conference Call Participants Scott Henry - ROTH Capital Operator Ladies and gentlemen, welcome to IRadimed Corporation Fourth Quarter and Full Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) Q4 2022 Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q4 Earnings Top Estimates

WINTER SPRINGS, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022. The Company also announced that its Board of Directors approved a special cash dividend of $1.05 per share on the Company's outstanding common stock. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend

WINTER SPRINGS, Fla., Jan. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 fourth quarter financial results before the market opens on Thursday, February 2, 2023.  IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd

iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love iRadimed (IRMD)

WINTER SPRINGS, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced selected preliminary financial results for the fourth quarter that ended December 31, 2022. Fourth-quarter revenue is expected to be approximately $14.9 million, up 25% from the prior year and above the Company's fourth-quarter guidance of $14.1 million - $14.8 million.

IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy iRadimed (IRMD) Now

Shockwave Medical

Tactile Systems

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

3 Medical Instruments Stocks With Potential to Outperform

IRadimed Corporation continues to re-rate to the downside despite robust fundamentals last quarter. Despite this, the market may have discounted the stock correctly looking at revenue, EPS estimates in our opinion.

iRadimed: Reduce To Hold, Price Visibility Around $28 More Certain

IRadimed Corporation (NASDAQ:IRMD ) Q3 2022 Earnings Conference Call November 3, 2022 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Operator Welcome to the IRadimed Corporation Third Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2022 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 20.83% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q3 Earnings and Revenues Top Estimates

WINTER SPRINGS, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems designed for use during MRI procedures.

IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results

Announces Preliminary Financial Results for Third Quarter 2022 Announces Preliminary Financial Results for Third Quarter 2022

IRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA

WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent.

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Doximity

Gilead Sciences

If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.

3 Healthcare Stocks With High Profit Margins

IRadimed Corporation (NASDAQ:IRMD ) Q2 2022 Earnings Conference Call July 29, 2022 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Jack Glenn – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

IRadimed Corporation (IRMD) CEO Roger Susi on Q2 2022 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates

WINTER SPRINGS, Fla., July 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results

WINTER SPRINGS, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

UPDATE - IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th

WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th

IRadimed presents us with the alternative risk premia that investors are rewarding in FY22. Bottom-line fundamentals are strengthening whilst the stock has diverged away from the medtech sector.

IRadimed: Reduce Equity Beta With Upside Capture

WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume responsibility for all areas of accounting and finance, including business planning and modeling, organizational resource planning, investor and analyst relations, and required reporting and related filings with the SEC.

News for iRadimed Stock (IRMD)